Albireo to Present at the Jefferies 2017 London Healthcare Conference

BOSTON, Nov. 09, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to make a corporate presentation and provide a business update at the Jefferies 2017 London Healthcare Conference on Thursday, November 16, 2017, at 10:40 a.m. GMT (5:40 a.m. ET).

A live audio webcast of the presentation will be accessible from the Investors page of Albireo’s website, http://ir.albireopharma.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events & Presentations section of the Investors page of Albireo’s website for at least two weeks following the event.

For more information about the conference, visit: www.jefferies.com.                  

About Albireo 
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes a Phase 3 product candidate, a Phase 2 product candidate and a product candidate for which an application for regulatory approval has been submitted in Japan. Albireo was spun out from AstraZeneca in 2008.

Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:
Hans Vitzthum                                    
LifeSci Advisors, LLC.                       
212-915-2568                                     

Media Contact:
Heather Anderson
6 Degrees
980-938-0260
[email protected]   

Source: Albireo Pharma, Inc.